Janani Jegatheesan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Janani Jegatheesan has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Sadhana Sharma
Department of Biochemistry, All India Institute of Medical Sciences, Patna, Bihar, India
2 shared publications Abhinash Kumar
Department of Biochemistry, All India Institute of Medical Sciences Patna, Bihar, India
1 shared publication- Ajit Kumar Saxena
All India Institute of Medical Sciences
1 shared publication Asgar Ali
Department of Biochemistry, All India Institute of Medical Sciences Patna, Bihar, India
1 shared publicationAshish Ranjan
Department of Biochemistry, All India Institute of Medical Sciences Patna, Bihar, India
1 shared publication- Ashish Ranjan
Department of Biochemistry, All India Institute of Medical Science, Patna 801507, India
1 shared publication
Latest Publications
- Open Access
- 13 December 2024
- Published by Scientific Scholar in Annals of the National Academy of Medical Sciences (India)
- Vol. 60, 261-266
Association of circulatory chemerin levels with the severity of pre-eclampsia: A systematic review and bootstrapped meta-analysis
Introduction: This study presents a systematic review and meta-analysis to investigate the association between circulating chemerin levels and the severity of preeclampsia (PE). Material and Methods: A thorough search was conducted across multiple databases, including PubMed/MEDLINE, SCOPUS, and the Cochrane Library, up to March 31, 2024, focusing on observational studies that compared chemerin levels in patients with severe versus mild PE. Two independent reviewers extracted mean and standard deviation (SD) values of chemerin levels from these studies. The quality and risk of bias of the included studies were assessed using the Newcastle–Ottawa Scale. Standardized mean differences (SMD) with 95% confidence intervals (CI) were calculated to evaluate the difference in chemerin levels between severe and mild PE groups. Sensitivity analyses were performed to address heterogeneity and ensure the reliability of the findings. Additionally, a bootstrapped meta-analysis with 1,000 and 10,000 simulations was conducted to further validate the results. Results: Six observational studies were included in the analysis. The findings revealed that patients with severe PE had significantly higher chemerin levels compared to those with mild PE (SMD 1.55, 95% CI 0.67–2.43, p < 0.0001). The bootstrapped meta-analysis supported the accuracy of these findings (SMD = 1.54, CI = 0.74–2.38). No publication bias was identified using Begg’s and Egger’s tests, and the sensitivity analysis confirmed the robustness of the results. Conclusion: This meta-analysis provides compelling evidence that chemerin levels are significantly elevated in patients with severe PE compared to those with mild PE. Further research is warranted to investigate the potential of circulating chemerin as a diagnostic marker for PE severity.
- 13 December 2024
- Published by Scientific Scholar in Annals of the National Academy of Medical Sciences (India)
- Vol. 60, 261-266
Open AccessAssociation of circulatory chemerin levels with the severity of pre-eclampsia: A systematic review and bootstrapped meta-analysis
Introduction: This study presents a systematic review and meta-analysis to investigate the association between circulating chemerin levels and the severity of preeclampsia (PE). Material and Methods: A thorough search was conducted across multiple databases, including PubMed/MEDLINE, SCOPUS, and the Cochrane Library, up to March 31, 2024, focusing on observational studies that compared chemerin levels in patients with severe versus mild PE. Two independent reviewers extracted mean and standard deviation (SD) values of chemerin levels from these studies. The quality and risk of bias of the included studies were assessed using the Newcastle–Ottawa Scale. Standardized mean differences (SMD) with 95% confidence intervals (CI) were calculated to evaluate the difference in chemerin levels between severe and mild PE groups. Sensitivity analyses were performed to address heterogeneity and ensure the reliability of the findings. Additionally, a bootstrapped meta-analysis with 1,000 and 10,000 simulations was conducted to further validate the results. Results: Six observational studies were included in the analysis. The findings revealed that patients with severe PE had significantly higher chemerin levels compared to those with mild PE (SMD 1.55, 95% CI 0.67–2.43, p < 0.0001). The bootstrapped meta-analysis supported the accuracy of these findings (SMD = 1.54, CI = 0.74–2.38). No publication bias was identified using Begg’s and Egger’s tests, and the sensitivity analysis confirmed the robustness of the results. Conclusion: This meta-analysis provides compelling evidence that chemerin levels are significantly elevated in patients with severe PE compared to those with mild PE. Further research is warranted to investigate the potential of circulating chemerin as a diagnostic marker for PE severity.
- Open Access
Emerging Role of Autophagy in Governing Cellular Dormancy, Metabolic Functions, and Therapeutic Responses of Cancer Stem Cells
Tumors are composed of heterogeneous populations of dysregulated cells that grow in specialized niches that support their growth and maintain their properties. Tumor heterogeneity and metastasis are among the major hindrances that exist while treating cancer patients, leading to poor clinical outcomes. Although the factors that determine tumor complexity remain largely unknown, several genotypic and phenotypic changes, including DNA mutations and metabolic reprograming provide cancer cells with a survival advantage over host cells and resistance to therapeutics. Furthermore, the presence of a specific population of cells within the tumor mass, commonly known as cancer stem cells (CSCs), is thought to initiate tumor formation, maintenance, resistance, and recurrence. Therefore, these CSCs have been investigated in detail recently as potential targets to treat cancer and prevent recurrence. Understanding the molecular mechanisms involved in CSC proliferation, self-renewal, and dormancy may provide important clues for developing effective therapeutic strategies. Autophagy, a catabolic process, has long been recognized to regulate various physiological and pathological processes. In addition to regulating cancer cells, recent studies have identified a critical role for autophagy in regulating CSC functions. Autophagy is activated under various adverse conditions and promotes cellular maintenance, survival, and even cell death. Thus, it is intriguing to address whether autophagy promotes or inhibits CSC functions and whether autophagy modulation can be used to regulate CSC functions, either alone or in combination. This review describes the roles of autophagy in the regulation of metabolic functions, proliferation and quiescence of CSCs, and its role during therapeutic stress. The review further highlights the autophagy-associated pathways that could be used to regulate CSCs. Overall, the present review will help to rationalize various translational approaches that involve autophagy-mediated modulation of CSCs in controlling cancer progression, metastasis, and recurrence.
Open AccessEmerging Role of Autophagy in Governing Cellular Dormancy, Metabolic Functions, and Therapeutic Responses of Cancer Stem Cells
Tumors are composed of heterogeneous populations of dysregulated cells that grow in specialized niches that support their growth and maintain their properties. Tumor heterogeneity and metastasis are among the major hindrances that exist while treating cancer patients, leading to poor clinical outcomes. Although the factors that determine tumor complexity remain largely unknown, several genotypic and phenotypic changes, including DNA mutations and metabolic reprograming provide cancer cells with a survival advantage over host cells and resistance to therapeutics. Furthermore, the presence of a specific population of cells within the tumor mass, commonly known as cancer stem cells (CSCs), is thought to initiate tumor formation, maintenance, resistance, and recurrence. Therefore, these CSCs have been investigated in detail recently as potential targets to treat cancer and prevent recurrence. Understanding the molecular mechanisms involved in CSC proliferation, self-renewal, and dormancy may provide important clues for developing effective therapeutic strategies. Autophagy, a catabolic process, has long been recognized to regulate various physiological and pathological processes. In addition to regulating cancer cells, recent studies have identified a critical role for autophagy in regulating CSC functions. Autophagy is activated under various adverse conditions and promotes cellular maintenance, survival, and even cell death. Thus, it is intriguing to address whether autophagy promotes or inhibits CSC functions and whether autophagy modulation can be used to regulate CSC functions, either alone or in combination. This review describes the roles of autophagy in the regulation of metabolic functions, proliferation and quiescence of CSCs, and its role during therapeutic stress. The review further highlights the autophagy-associated pathways that could be used to regulate CSCs. Overall, the present review will help to rationalize various translational approaches that involve autophagy-mediated modulation of CSCs in controlling cancer progression, metastasis, and recurrence.